maintain market perform rate share
follow review result result came
ahead consensu believ share fulli valu flat
sale trend absent major inflect new product sale
pipelin success overal new product categori like cgrp
get crowd competit key
pipelin area kra bcma inflamm would take
wait-and-se approach current valuat continu
concern durabl respons target kra
competit t-cell engag target bcma high
respons hurdl set competitor tezepelumab could greater
potenti allergi asthma competit
signific non-gaap estim vs prior
ep estim vs prior
report result yesterday market close
provid updat key oper pipelin strateg
initi non-gaap ep ahead consensu
total revenu vs consensu
updat ep guidanc
increas revenu guidanc prior
guidanc total net sale decreas
year-over-year consensu sale aranesp
enbrel vs consensu in-lin sale
consensu nplate vs consensu
consensu sale neulasta vs
consensu vs consensu parsabiv
vs consensu non- ep
vs prior
continu page
compani data secur llc estim reuter
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
focu key trend assumpt note sale declin volum growth newer
product slightli outpac declin matur product sale grew year-over-year
yoy driven volum growth invest pipelin new product growth
expens increas yoy driven primarili increas spend research earli oncolog
pipelin off-set partial decreas spend support market product sg expens
decreas yoy driven primarili lower gener administr expens well end certain
amort intang asset overal non-gaap oper margin declin yoy
free cash flow saw slight increas driven primarili favor chang work
capit repatha sale increas yoy driven higher unit demand partial off-set lower net
sell price enbrel beat driven high net sell price favor chang account
estim partial off-set lower unit demand parsabiv uptak continu outperform note strong
util independ mid-size dialysi provid xgeva uptak continu benefit
label expans myeloma amgn recent launch bone franchis product even perform
well japan aimovig remain lead cgrp total prescript paid demand
increas
increas commit genet join uk biobank consortium decod
subsidiari contribut sequenc whole genom approxim individu contrast
elect exit neurosci inflamm partner azn complet
enrol phase navig trial tezepelumab monoclon antibodi target thymic
stromal lymphopoietin antagonist adolesc adult subject sever uncontrol asthma
expect commun top-lin annual exacerb rate aerr data late data
late also expect companion trial tezepelumab steroid-depend asthma
compani also evalu tezepelumab atop dermat data
chronic obstruct pulmonari diseas data novel bispecif antibodi peptid
conjug target ico ligand baff compani enrol subject system lupu
erythematosu random one three dose level vs placebo ahead
data complet enrol phase trial rheumatoid arthriti ra
also evalu mutein ra data expect vs prior
oncolog note phase non-smal cell lung cancer expans cohort kra
inhibitor enrol briskli phase kra colorect cancer cohort enrol
data tumor type expect also note compani initi
numer combin studi expect report top-lin data
half-lif extend hle bite acut myeloid leukemia well data
gener bite target egfrviii glioblastoma hle bcma bite
expect report data also note recent list phase trial
hle bite develop posit gastric gastroesophag cancer final biosimilar
note progress toward bsufa date infliximab biosimilar
compani expect file bla rituximab biosimilar
price target nc
arriv price target appli multipl ep estim risk includ
greater expect eros base biolog busi competit kyproli gener
velcad emerg myeloma treatment failur gain approv proprietari biosimilar
expens price-to-earnings basi rel growth view face signific headwind
biosimilar brand competit legaci franchis
larg cap global commercial-stag biotechnolog compani discov develop biolog
small molecul drug specialti physician discoveri pipelin led compani
broaden focu oncolog immune-medi inflammatori diseas renal diseas includ
bone diseas cardiovascular neurolog diseas addit taken lead posit
develop biosimilar compani face near-term biosimilar competit legaci
